Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.

2.

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22.

3.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. Review.

4.

Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.

Kremer JM, Genovese MC, Keystone E, Taylor PC, Zuckerman SH, Ruotolo G, Schlichting DE, Crotzer VL, Nantz E, Beattie SD, Macias WL.

Arthritis Rheumatol. 2017 May;69(5):943-952. doi: 10.1002/art.40036.

5.

Derivation and characterization of monoclonal antibodies against human folypolyglutamate synthetase.

Dotzlaf J, Carpenter J, Luo S, Miles RR, Fisher D, Qian YW, Ehsani M, Wang X, Lin A, McClure DB, Chen VJ, Zuckerman SH.

Hybridoma (Larchmt). 2007 Jun;26(3):155-61.

PMID:
17600497
6.

Derivation and characterization of a monoclonal antibody against human glycinamide ribonucleotide formyltransferase.

Dotzlaf J, Carpenter J, Luo S, Roberts EF, Solenberg PJ, Qian YW, Lin A, He X, Sandusky GE, McClure DB, Chen VJ, Zuckerman SH.

Hybridoma (Larchmt). 2006 Jun;25(3):139-44.

PMID:
16796460
7.

Gamma interferon: a central mediator in atherosclerosis.

Leon ML, Zuckerman SH.

Inflamm Res. 2005 Oct;54(10):395-411. Review.

PMID:
16283107
8.

Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.

Chintalacharuvu S, Evans GF, Shih C, Bryant HU, Sandusky GE, Zuckerman SH.

Clin Exp Rheumatol. 2005 Jul-Aug;23(4):438-46.

PMID:
16095110
9.

Post-transcriptional regulation of macrophage ABCA1, an early response gene to IFN-gamma.

Alfaro Leon ML, Evans GF, Farmen MW, Zuckerman SH.

Biochem Biophys Res Commun. 2005 Jul 29;333(2):596-602.

PMID:
15946645
11.

Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.

Christe M, Jin N, Wang X, Gould KE, Iversen PW, Yu X, Lorenz JN, Kadambi V, Zuckerman SH, Bloem LJ.

J Mol Cell Cardiol. 2004 Sep;37(3):705-15.

PMID:
15350844
12.

Histone deacetylase inhibition results in decreased macrophage CD9 expression.

Wang XQ, Alfaro ML, Evans GF, Zuckerman SH.

Biochem Biophys Res Commun. 2002 Jun 14;294(3):660-6.

PMID:
12056820
14.

Interferon-gamma-mediated downregulation of cholesterol efflux and ABC1 expression is by the Stat1 pathway.

Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH.

Arterioscler Thromb Vasc Biol. 2002 May 1;22(5):e5-9.

PMID:
12006410
15.

Down-regulation of macrophage CD9 expression by interferon-gamma.

Wang XQ, Evans GF, Alfaro ML, Zuckerman SH.

Biochem Biophys Res Commun. 2002 Jan 25;290(3):891-7.

PMID:
11798156
16.
17.

TGF-beta reduced binding of high-density lipoproteins in murine macrophages and macrophage-derived foam cells.

Zuckerman SH, Panousis C, Evans G.

Atherosclerosis. 2001 Mar;155(1):79-85.

PMID:
11223429
18.
19.
20.
21.

Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human ApoB100xCETP transgenic mice.

Zuckerman SH, Evans GF, Schelm JA, Eacho PI, Sandusky G.

Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1476-83.

PMID:
10364078
22.

Preclinical biology of recombinant human hemoglobin, rHb1.1.

Zuckerman SH, Doyle MP, Gorczynski R, Rosenthal GJ.

Artif Cells Blood Substit Immobil Biotechnol. 1998 May;26(3):231-57. Review.

PMID:
9635118
24.

In vivo dexamethasone effects on neutrophil effector functions in a rat model of acute lung injury.

O'Leary EC, Evans GF, Zuckerman SH.

Inflammation. 1997 Dec;21(6):597-608.

PMID:
9429907
28.

Estriol: a potent regulator of TNF and IL-6 expression in a murine model of endotoxemia.

Zuckerman SH, Ahmari SE, Bryan-Poole N, Evans GF, Short L, Glasebrook AL.

Inflammation. 1996 Dec;20(6):581-97.

PMID:
8979148
29.

The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.

Apelgren LD, Bailey DL, Fouts RL, Short L, Bryan N, Evans GF, Sandusky GE, Zuckerman SH, Glasebrook A, Bumol TF.

Cell Immunol. 1996 Oct 10;173(1):55-63.

PMID:
8871601
32.

Estrogen-induced alterations in lipoprotein metabolism in autoimmune MRL/lpr mice.

Zuckerman SH, Bryan-Poole N.

Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1556-62.

PMID:
7583527
33.

In vitro detection of apoptotic stimuli by use of the HL-60 myeloid leukemic cell line.

Shellhaas JL, Zuckerman SH.

Clin Diagn Lab Immunol. 1995 Sep;2(5):598-603.

34.
35.
36.
37.
38.

Exogenous glucocorticoids increase macrophage secretion of apo E by cholesterol-independent pathways.

Zuckerman SH, Evans GF, O'Neal L.

Atherosclerosis. 1993 Oct;103(1):43-54.

PMID:
8280184
39.

Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-beta.

Zuckerman SH, Evans GF, O'Neal L.

Atherosclerosis. 1992 Oct;96(2-3):203-14.

PMID:
1466652
41.
42.

Transcriptional inhibition of endotoxin-induced monokine synthesis following heat shock in murine peritoneal macrophages.

Snyder YM, Guthrie L, Evans GF, Zuckerman SH.

J Leukoc Biol. 1992 Feb;51(2):181-7.

PMID:
1431555
43.

Glucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance.

Evans GF, Zuckerman SH.

Eur J Immunol. 1991 Sep;21(9):1973-9.

PMID:
1716205
45.
46.

Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models.

Evans GF, Snyder YM, Butler LD, Zuckerman SH.

Circ Shock. 1989 Dec;29(4):279-90.

PMID:
2598414
47.
48.
49.

Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression.

Zuckerman SH, Evans GF, Snyder YM, Roeder WD.

J Immunol. 1989 Aug 15;143(4):1223-7.

PMID:
2501392

Supplemental Content

Loading ...
Support Center